US › Healthcare

Lexaria Bioscience Corp (LEXX)

US · Healthcare · Biotechnology

$5.62+18.32%
Last close · 2026-08-04

Latest quarter · ended 2026-05-31

Net profit
$-2.0M
Profit YoY
+47.4%
EPS
$-0.08
EPS estimate
$-0.06

EPS came in at -0.08 against a street estimate of -0.06 — a miss of 33.3%.

Key statistics

Market cap
$9.7M
Forward P/E
0.0
P/B
2.07
Book value
$0.19
EPS (TTM)
$-5.10
52-week high
$6.39
52-week low
$0.46
50-day MA
$8.73
200-day MA
$11.43
Beta
0.34

Analyst view

Analysts rate Lexaria Bioscience Corp a buy (2 buy, 0 hold, 0 sell out of 2) with an average price target of $52.50.

Shareholding

Insiders
3.32%
Institutions
6.04%

Largest institutional holders

FundStake
Invenomic Capital Management, LP1.78%
Geode Capital Management, LLC1.19%
Vanguard Capital Management, LLC0.90%
The Toronto-Dominion Bank0.56%
Vanguard Fiduciary Trust Co0.38%
UBS Group AG0.21%
State Street Corp0.16%
BlackRock Inc0.11%

See the full picture

Technicals, trade setups with a published hit rate, $AI analysis and earnings-call summaries for Lexaria Bioscience Corp — free to start.

Google PlayApp Store

Other Healthcare companies

Eli Lilly and CompanyJohnson & JohnsonAbbVie IncUnitedHealth Group IncorporatedMerck & Company IncNovartis AG ADRAstraZeneca PLCThermo Fisher Scientific IncNovo Nordisk A/SAmgen IncAbbott LaboratoriesGilead Sciences Inc

Data updated 2026-08-05.